Neuroimaging in Parkinson's Disease

NeuroRx

Volumn 1, Issue 2, 2004, Pages 243-254

  Brooks, David J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

dopamine; neuroprotection; Parkinson's disease; Positron emission tomography; progression; SPECT

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CLINICAL EXAMINATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; NEUROIMAGING; NEUROPROTECTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; BRAIN; REVIEW; SCINTISCANNING;

BRAIN; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 23844456320     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.2.243     Document Type: Article

References (94)

1. Hu M., White S., Herlihy A., et al. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 56 (2001) 1195-1200
2. Hutchinson M., and Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. AJNR Am J Neuroradiol 21 (2000) 697-701
3. Schrag A., Good C., Miszkiel K., et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54 (2000) 697-702
4. Schulz J., Skalej M., Wedekind D., et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 45 (1999) 65-74
5. Seppi K., Schocke M., Esterhammer R., et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60 (2003) 922-927
6. Jellinger K. The pathology of parkinsonism. In: Marsden C., and Fahn S. (Eds). Movement disorders 2. Ed 1 (1987), Butterworths, London 124-165
7. Fearnley J., and Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
8. Kish S., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 318 (1988) 876-880
9. Braak H., Tredici K., Rub U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
10. Jellinger K., Seppi K., Wenning G., and Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109 (2002) 329-339
11. McKeith I., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
12. Morrish P., Sawle G., and Brooks D. Clinical and [18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59 (1995) 597-600
13. Rakshi J., Uema T., Ito K., et al. Frontal, striatal, and midbrain dopaminergic function in early and advanced Parkinson's disease: a 3D 18F-dopa PET study. Brain 122 (1999) 1637-1650
14. Brooks D., Ibañez V., Sawle G., et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 28 (1990) 547-555
15. Leenders K., Salmon E., Tyrrell P., et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47 (1990) 1290-1298
16. Bernheimer H., Birkmayer W., Hornykiewicz O., et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological, and neurochemical correlations. J Neurol Sci 20 (1973) 415-455
17. Lindvall O., and Bjorklund A. Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway. Brain Res 172 (1979) 169-173
18. Whone A., Moore R., Piccini P., and Brooks D. Plasticity in the nigropallidal pathway in Parkinson's disease: an 18F-dopa PET study. Ann Neurol 53 (2003) 206-213
19. Frost J., Rosier A., Reich S., et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34 (1993) 423-431
20. Rinne J., Bergman J., Ruotinnen H., et al. Striatal uptake of a novel PET ligand, [18F]b-CFT, is reduced in early Parkinson's disease. Synapse 31 (1999) 119-124
21. Guttman M., Burkholder J., Kish S., et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 48 (1997) 1578-1583
22. Marek K., Seibyl J., Zoghbi S., et al. [I-123] β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinsons disease. Neurology 46 (1996) 231-237
23. Benamer H., Patterson J., Wyper D., et al. Correlation of Parkinson's disease severity and duration with I-123-FP-CIT SPECT striatal uptake. Movement Disorders 15 (2000) 692-698
24. Benamer T., Patterson J., Grosset D., et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT imaging: the [123I]-FP-CIT study group. Mov Disord 15 (2000) 503-510
25. Fischman A., Bonab A., Babich J., et al. [C-11, I-127] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 39 (2001) 332-342
26. Mozley P., Schneider J., Acton P., et al. Binding of [Tc-99m]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 41 (2000) 584-589
27. Vingerhoets F., Schulzer M., Caine D., and Snow B. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann Neurol 41 (1997) 58-64
28. Otsuka M., Ichiya Y., Kuwabara Y., et al. Differences in the reduced 18F-dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 136 (1996) 169-173
29. Tatsch K., Schwarz J., Mozley P., et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [I-123]IPT and SPECT. Eur J Nucl Med 24 (1997) 415-421
30. Lee C., Samii A., Sossi V., et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47 (2000) 493-503
31. Doder M., Rabiner E., Turjanski N., et al. Tremor in Parkinson's disease and serotonergic dysfunction: an (11)C-WAY 100635 PET study. Neurology 60 (2003) 601-605
32. Golbe L. The genetics of Parkinson's disease: a reconsideration. Neurology 40 Suppl 3 (1990) 7-16
33. Piccini P., Morrish P., Turjanski N., et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa PET study. Ann Neurol 41 (1997) 222-229
34. Piccini P., Burn D., Ceravalo R., et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45 (1999) 577-582
35. Khan N., Brooks D., Pavese N., et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125 (2002) 2248-2256
36. Hilker R., Klein C., Ghaemi M., et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 49 (2001) 367-376
37. Scherfler C., Khan N., Pavese N., et al. Striatal and extrastriatal PET measurements of dopa metabolism and D2 receptor status in patients with parkin gene mutations. Neurology 58 Suppl 3 (2002) A201
38. Banati R., Myers R., and Kreutzberg G. PK ('peripheral benzodiazepine')-binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 26 (1997) 77-82
39. McGeer P., Itagaki S., Boyes B., and McGeer E. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
40. Gerhard A., Banati R., Cagnin A., and Brooks D. In vivo imaging of activated microglia with [C-11]PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease. Neurology 56 Suppl 3 (2001) A270
41. Snow B., Tooyama I., McGeer E., et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34 (1993) 324-330
42. Pate B., Kawamata T., Yamada T., et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34 (1993) 331-338
43. Rakshi J., Bailey D., Morrish P., and Brooks D. Implementation of 3D acquisition, reconstruction, and analysis of dynamic [18F] Fluorodopa studies. In: Myers R., Cunningham V., Bailey D., and Jones T. (Eds). Quantification of brain function using PET (1996), Academic Press, San Diego 82-87
44. Ceravolo R., Piccini P., Bailey D., et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43 (2002) 201-207
45. Turjanski N., Lees A., and Brooks D. Striatal dopaminergic receptor dysfunction in patients with restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 52 (1999) 932-937
46. Innis R., Marek K., Sheff K., et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [I-123]β-CIT. Mov Disord 14 (1999) 436-442
47. Vingerhoets F., Snow B., Lee C., et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36 (1994) 759-764
48. Morrish P., Rakshi J., Sawle G., and Brooks D. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64 (1998) 314-319
49. Nurmi E., Ruottinen H., Bergman J., et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16 (2001) 608-615
50. Nurmi E., Ruottinen H., Kaasinen V., et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand. Ann Neurol 47 (2000) 804-808
51. Marek K., Innis R., van Dyck C., et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 (2001) 2089-2094
52. Winogrodzka A., Bergmans P., Booij J., et al. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 108 (2001) 1011-1019
53. Schwarz J., Tatsch K., Linke R., et al. Measuring the decline of dopamine transporter binding in patients with Parkinson's disease using 123I-IPT and SPECT. Neurology 48 Suppl 2 (1997) A208
54. Olanow C., Jenner P., and Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44 Suppl1 (1998) S167-S174
55. Whone A., Watts R., Stoessl J., et al. Slower progression of PD with ropinirol versus L-dopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
56. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa Parkinson disease progression. JAMA 287 (2002) 1653-1661
57. Ahlskog J. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 60 (2003) 381-389
58. Hadjiconstantinou M., Wemlinger T., Sylvia C., et al. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 60 (1993) 2175-2180
59. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA trial. Neurology 60 Suppl 1 (2003) A80-A81
60. Lindvall O. Cerebral implantation in movement disorders: state of the art. Mov Disord 14 (1999) 201-205
61. Piccini P., Brooks D., Bjorklund A., et al. Dopamine release from nigral transplants visualised in vivo in a Parkinson's patient. Nat Neurosci 2 (1999) 1137-1140
62. Wenning G., Odin P., Morrish P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42 (1997) 95-107
63. Brundin P., Pogarell O., Hagell P., et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 (2000) 1380-1390
64. Remy P., Samson Y., Hantraye P., et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 38 (1995) 580-588
65. Hauser R., Freeman T., Snow B., et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56 (1999) 179-187
66. Kordower J., Freeman T., Chen E., et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 13 (1998) 383-393
67. Freed C., Greene P., Breeze R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
68. Olanow C., Goetz C., Kordower J., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
69. Gill S., Patel N., Hotton G., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 (2003) 589-595
70. De La Fuente-Fernandez R., Pal P., Vingerhoets F., et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 107 (2000) 49-57
71. Playford E., and Brooks D. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev 4 (1992) 144-171
72. Rinne U., Laihinen A., Rinne J., et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 5 (1990) 55-59
73. Antonini A., Schwarz J., Oertel W., et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 44 (1994) 1325-1329
74. Turjanski N., Lees A., and Brooks D. PET studies on striatal dopaminergic receptor binding in drug naive and L-dopa treated Parkinson's disease patients with and without dyskinesia. Neurology 49 (1997) 717-723
75. Kishore A., De la Fuente-Fernández R., Snow B., et al. Levodopa-induced dyskinesias in idiopathic parkinsonism (IP): a simultaneous PET study of dopamine D1 and D2 receptors. Neurology 48 (1997) A327
76. Breier A., Su T., Saunders R., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from novel positron emission tomography method. Proc Natl Acad Sci USA 94 (1997) 2569-2574
77. Torstenson R., Hartvig P., Långström B., et al. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 41 (1997) 334-340
78. De La Fuente-Fernandez R., Lu J., Sossi V., et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 49 (2001) 298-303
79. Henry B., and Brotchie J. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 9 (1996) 149-158
80. Nisbet A., Foster O., Kingsbury A., et al. Preproenkephalin and preprotachykinin messenger-RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66 (1995) 361-376
81. Jolkkonen J., Jenner P., and Marsden C. L-dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol Brain Res 32 (1995) 297-307
82. Lavoie B., Parent A., and Bedard P. Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys. Can J Neurol Sci 18 (1991) 373-375
83. Piccini P., Weeks R., and Brooks D. Opioid receptor binding in Parkinson's patients with and without levodopa-induced dyskinesias. Ann Neurol 42 (1997) 720-726
84. Whone A., Rabiner E., Arahata Y., et al. Reduced substance P binding in Parkinson's disease complicated by dyskinesias: an F-18-L829165 PET study. Neurology 58 Suppl 3 (2002) A488-A489
85. Korczyn A. Dementia in Parkinson's disease. J Neurol 248 Suppl 3 (2001) III1-III4
86. Miletich R., Chan T., Gillespie M., et al. Contralateral basal ganglia metabolism is abnormal in hemiparkinsonian patients. An FDG-PET study. Neurology 38 (1988) S260
87. Wolfson L., Leenders K., Brown L., and Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 35 (1985) 1399-1405
88. Eidelberg D., Moeller J., Dhawan V., et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14 (1994) 783-801
89. Eidelberg D., Moeller J., Ishikawa T., et al. Assessment of disease severity in Parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 36 (1995) 378-383
90. Peppard R., Martin W., Guttman M., et al. The relationship of cerebral glucose metabolism to cognitive deficits in Parkinson's disease. Neurology 38 Suppl 1 (1988) 364
91. Kuhl D., Metter E., and Benson D. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia. J Cereb Blood Flow Metab 5 (1985) S169-S170
92. Bohnen N., Minoshima S., Giordani B., et al. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 52 (1999) 541-546
93. Hu M., Taylor-Robinson S., Chaudhuri K., et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 123 (2000) 340-352
94. Walker Z., Costa D., Walker R., et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73 (2002) 134-140